2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Specimen Collection for the BD Vaginal Panel
Vaginitis | Webinars & Videos
Specimen Collection for the BD Vaginal Panel
Contemporary Obgyn: Not all HPV genotypes pose the same risk for disease
Cervical Cancer | News & Updates
Contemporary OB/GYN: Not all HPV genotypes pose the same risk for disease
ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women
Cervical Cancer | News & Updates
ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women